Redeye provides a research update following the Q1 report recently published by Initiator Pharma. While the company reported an increased OPEX as a direct result of the ongoing clinical study, we believe that it will continue to operate at a cost-efficient rate and see no reason for worry. More importantly, at least half of the targeted 24-patient cohort in the phase IIa study with pudafensine in vulvodynia has now been dosed. We are encouraged to learn that the trial is progressing according to plan with topline results guided for late 2026.
LÄS MER
